Safety and Efficacy of ACU-D1 in the Treatment of Acne Rosacea

Summary

The study evaluated the safety, tolerability, and efficacy of ACCU-D1 when applied twice daily for 12 weeks in adult participants with moderate to severe acne rosacea. Two-third of the participants received ACCU-D1 while one-third of the participants received vehicle control.

Timeline

Start

2017-11-28

Primary completion

2018-06-05

Completion

2018-06-18

Outcome

Missed primary endpoint

registry analysis (superiority test); ACU-D1 Ointment vs ACU-D1 Ointment Vehicle; p = 0.366; Difference of Least Squares (LS) Mean 1.8 (95% CI -2.162 to 5.727) NCT03064438 ↗

Publications

• Jackson JM, Coulon R, Arbiser JL. Evaluation of a First-in-Class Proteasome Inhibitor in Patients With Moderate to Severe Rosacea. J Drugs Dermatol. 2021 Jun 1;20(6):660-664. doi: 10.36849/JDD.2021.5925.

Drugs

Indications